Skeletal muscle disorders of glycogenolysis and glycolysis account for most of the conditions collectively termed glycogen storage diseases (GSDs). These disorders are rare (incidence 1 in 20,000-43,000 live births), and are caused by autosomal or X-linked recessive mutations that result in a specific enzyme deficiency, leading to the inability to utilize muscle glycogen as an energy substrate. McArdle disease (GSD V) is the most common of these disorders, and is caused by mutations in the gene encoding muscle glycogen phosphorylase. Symptoms of McArdle disease and most other related GSDs include exercise intolerance, muscle contracture, acute rhabdomyolysis, and risk of acute renal failure. Older patients may exhibit muscle wasting and wea...
McArdle Disease (Glycogen Storage Disorder Type V) is one of the most common inherited genetic alter...
McArdle disease (glycogen storage disease type V, OMIM database number 232600) may provide the ultim...
Twenty participants, including one patient representative, from 9 countries (UK, Spain, France, Swed...
Skeletal muscle disorders of glycogenolysis and glycolysis account for most of the conditions collec...
McArdle disease (glycogen storage disease type V) is caused by inherited deficiency of a key enzyme ...
McArdle disease or Glycogen Storage Disease type V (GSD V; myophosphorylase deficiency; MIM 232600) ...
McArdle disease (glycogen storage disease type V) is an inborn error of energy metabolism in the mus...
McArdle disease (glycogen storage disease Type V; MD) is a metabolic myopathy caused by a deficiency...
McArdle disease is arguably the paradigm of exercise intolerance in humans. This disorder is caused ...
McArdle disease, also known as glycogen storage disease type V (GSDV), is characterized by exercise ...
McArdle’s disease (Glycogen storage disease type V) is a rare inherited autosomal recessive disease ...
McArdle’s Disease, or Glycogen Storage Disease Type V, is the result of a deficiency in one of...
McArdle disease is arguably the paradigm of exercise intolerance in humans. This disorder is caused ...
McArdle disease is caused by recessive mutations in the gene encoding muscle glycogen phosphorylase ...
International audienceGlycogen storage disease type XV (GSD XV) is a recently described muscle glyco...
McArdle Disease (Glycogen Storage Disorder Type V) is one of the most common inherited genetic alter...
McArdle disease (glycogen storage disease type V, OMIM database number 232600) may provide the ultim...
Twenty participants, including one patient representative, from 9 countries (UK, Spain, France, Swed...
Skeletal muscle disorders of glycogenolysis and glycolysis account for most of the conditions collec...
McArdle disease (glycogen storage disease type V) is caused by inherited deficiency of a key enzyme ...
McArdle disease or Glycogen Storage Disease type V (GSD V; myophosphorylase deficiency; MIM 232600) ...
McArdle disease (glycogen storage disease type V) is an inborn error of energy metabolism in the mus...
McArdle disease (glycogen storage disease Type V; MD) is a metabolic myopathy caused by a deficiency...
McArdle disease is arguably the paradigm of exercise intolerance in humans. This disorder is caused ...
McArdle disease, also known as glycogen storage disease type V (GSDV), is characterized by exercise ...
McArdle’s disease (Glycogen storage disease type V) is a rare inherited autosomal recessive disease ...
McArdle’s Disease, or Glycogen Storage Disease Type V, is the result of a deficiency in one of...
McArdle disease is arguably the paradigm of exercise intolerance in humans. This disorder is caused ...
McArdle disease is caused by recessive mutations in the gene encoding muscle glycogen phosphorylase ...
International audienceGlycogen storage disease type XV (GSD XV) is a recently described muscle glyco...
McArdle Disease (Glycogen Storage Disorder Type V) is one of the most common inherited genetic alter...
McArdle disease (glycogen storage disease type V, OMIM database number 232600) may provide the ultim...
Twenty participants, including one patient representative, from 9 countries (UK, Spain, France, Swed...